The metabolic dysregulation seen in MASLD and MASH generates a pro-atherogenic milieu, including systemic inflammation, oxidative stress, insulin resistance, a pro-atherogenic lipid profile as well as endothelial dysfunction. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.